[A20-13] Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2020
Project no.:
A20-13
Commission:
Commission awarded on 14.02.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Treatment-naive adults with metastatic non-small cell lung cancer with activating EGFR mutations
EGFR mutations Del19 or L858R: hint of lesser benefit versus appropriate comparator therapy; other EGFR mutations: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G15-02 | Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A16-23 | Ramucirumab - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-73 | Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-11 | Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-10 | Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |